Diagnosis and management of neurally mediated syncope and related conditions in adolescents

Journal of Adolescent Health

Volumn 28, Issue 1, 2001, Pages 2-9

  Boehm, Kathryn E ^a   Morris, Edith J ^a   Kip, Katrinka T ^b   Karas, Barry ^a   Grubb, Blair P ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b Children's Heart   (United States)

Author keywords

Adolescents; Chronic fatigue; Neurally mediated syncope; Neurocardiogenic syncope; Postural orthostatic tachycardia syndrome; Syncope

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAFFEINE; CITALOPRAM; CORTICOSTEROID; DISOPYRAMIDE; FLUDROCORTISONE; FLUOXETINE; METHYLPHENIDATE; MIDODRINE; NEFAZODONE; PAROXETINE; PLACEBO; PSEUDOEPHEDRINE; RECOMBINANT ERYTHROPOIETIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADOLESCENCE; ADOLESCENT; ADULT; AUTONOMIC DYSFUNCTION; BLOOD PRESSURE; BRADYCARDIA; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; FATIGUE; HEART PACING; HUMAN; MAJOR CLINICAL STUDY; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYNCOPE; TACHYCARDIA; TILT TABLE TEST;

ADOLESCENT; BIOFEEDBACK (PSYCHOLOGY); DIAGNOSIS, DIFFERENTIAL; HUMANS; POSTURE; PSYCHOPHYSIOLOGY; SYNCOPE, VASOVAGAL; TILT-TABLE TEST;

EID: 0035196171     PISSN: 1054139X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1054-139X(00)00153-1     Document Type: Review

References (112)

1. Ventricular tachycardia in children
2. Rhythm disturbances in hypertrophic cardiomyopathy: Prevalence, relation to symptoms and management
3. Syncope
4. Prolonged Q-T interval: What does it mean?
5. Psychiatric syncope: A new look at an old disease
6. Syncope and seizures of psychogenic origin: Identification with upright tilt table testing
7. Right ventricular cardiomyopathy and sudden death in young people
8. Seizure disorders
9. Syncope in the child and adolescent
10. The diagnosis and management of syncope in children and adolescents
11. Evaluation of patients with syncope: Focus on age-related differences. Part II-diagnostic approaches
12. A prospective evaluation of pediatric patients with syncope
13. Syncope
14. Head-upright tilt table testing for children with vasovagal syncope
15. Cardiovascular aspects of neurally mediated syncope in adolescents
16. Impairment of physical and psychosocial function in recurrent syncope
17. Neurocardiogenic syncope - Evaluation and management
18. Evaluation of patients with syncope: Focus on age-related differences. Part I - Etiologies
19. Lack of variation in venous tone potentiates vasovagal syncope
20. Mechanisms of vasovagal syncope: Relevance to postflight orthostatic intolerance
21. The Bezold-Jarish reflux revisited: Clinical implications of inhibitory reflexes originating in the heart
22. An overview of malignant vasovagal syncope and classification of tilt testing results
23. Neurocardiogenic syncope
24. Evaluating unexplained syncope with upright tilt testing
25. Syncope: Physiological considerations and an analysis of the clinical characteristics in 510 patients
26. Time frequency dynamics in neurally mediated syncope
27. Spectral analysis of heart rate in vasovagal syncope: The autonomic nervous system in vasovagal syncope
28. Neurocardiogenic syncope: What role for serotonin?
29. Serotonin and syncope: An emerging connection?
30. Neurally mediated syncope and serotonin reuptake inhibitors
31. Low blood pressure, low mood?
32. Psychiatric symptoms and low blood pressure: More evidence for an association
33. Low blood pressure and depression in older men: A population based study
34. Psychiatric illness in patients with syncope
35. Medically unexplained syncope: Relationship to psychiatric illness
36. Syncope as a conversion mechanism
37. Head-up tilt: A useful test for investigating unexplained syncope
38. Head-upright tilt table testing: A safe and easy way to assess neurocardiogenic syncope
39. Tilt table testing for evaluation of neurally mediated (cardioneurogenic) syncope: Rationale and proposed protocols
40. Reproducibility of a symptomatic response to upright tilt in young patients with unexplained syncope
41. Utility of upright tilt table testing in the evaluation and management of syncope of unknown origin
42. The use of head-upright tilt table testing in the evaluation and management of syncope in children and adolescents
43. Reproducibility of head upright tilt table test results in patients with syncope
44. Cardiovascular and catecholamine responses to head-up tilt in the diagnosis of recurrent unexplained syncope in elderly patients
45. Pathophysiological aspects of neurocardiogenic syncope: Current concepts and new perspectives
46. Head-up tilt for the evaluation of syncope of unknown origin in children
47. Upright body tilt for evaluation of patients with recurrent, unexplained syncope
48. Abnormal responses to orthostatic testing in children and adolescents with recurrent unexplained syncope
49. Head-upright tilt table testing in children with unexplained syncope
50. Methodology of isoproterenol-tilt table testing in patients with syncope
51. Circulatory and catecholamine changes during head-up tilt testing in neurocardiogenic (vasovagal) syncope
52. Tilt test for diagnosis of unexplained syncope in pediatric patients
53. Upright postures and isoproterenol infusion for provocation of neurocardiogenic syncope: A comparison of standing and head-up tilting
54. Methodology of head-up tilt testing in patients with unexplained syncope
55. ACC expert consensus document: Tilt table testing for assessing syncope
56. Reproducibility of head-up tilt-table testing for eliciting susceptibility to neurally mediated syncope in patients without structural heart disease
57. Head-up tilt test: A highly sensitive, specific test for children with unexplained syncope
58. Head up tilt testing in children who faint
59. Heart rate and blood pressure response to upright tilt in young patients with unexplained syncope
60. Orthostatic versus electrophysiologic testing in unexplained syncope in children and adolescents
61. The economic burden of unrecognized vasodepressor syncope
62. Is neurally mediated hypotension an unrecognised cause of chronic fatigue?
63. Orthostatic intolerance in adolescent chronic fatigue syndrome
64. Diagnosis and management of neurocardiogenic syncope
65. Acute pan-dysautonomic syncope: Presentation, course and management
66. Postpartum syncope
67. The postural orthostatic tachycardia syndrome: A neurocardiogenic variant identified during head up tilt table testing
68. The postural orthostatic tachycardia syndrome: A potentially treatable cause of chronic fatigue, exercise intolerance, and cognitive impairment in adolescents
69. Evaluation and treatment of patients with unexplained syncope
70. Acute and long-term beta-adrenergic blockade for patients with neurocardiogenic syncope
71. Use of intravenous esmolol to predict efficacy of beta-adrenergic blocker therapy in patients with neurocardiogenic syncope
72. Efficacy of different treatment strategies for neurocardiogenic syncope
73. Efficacy of pindolol for treatment of vasovagal syncope
74. Tilt table testing and oral metoprolol therapy in young patients with unexplained syncope
75. The effectiveness of beta-blockade and its influence on heart rate variability in vasovagal patients
76. Usefulness of disopyramide for prevention of upright tilt-induced hypotension-bradycardia
77. Low dose disopynamide often fails to prevent neurogenic syncope during head-up tilt testing
78. Usefulness of head-up tilt test in evaluating patients with syncope of unknown origin and negative electrophysiologic study
79. Use of sertraline hydrochloride in the treatment of refractory neurocardiogenic syncope in children and adolescents
80. The role of serotonin re-uptake inhibitors in preventing recurrent unexplained childhood syncope - A preliminary report
81. Efficacy of alpha-adrenergic agonist therapy for prevention of pediatric neurocardiogenic syncope
82. A case of vasovagal syncope with convulsions - The effects of midodrine hydrochloride
83. Observations on midodrine in a case of vasodepressor neurogenic syncope
84. Therapeutic effect of midodrine in hypotensive orthostatic circulatory dysregulation
85. The pharmacological properties of midodrine and its clinical application in patients with hypotensive circulatory disturbance
86. The use of midodrine in the treatment of the orthostatic syndrome
87. Midodrine: A new agent in the management of idiopathic orthostatic hypotension and Shy-Drager syndrome
88. Efficacy of midodrine hydrochloride in neurocardiogenic syncope refractory to standard therapy
89. Cardiac pacing for prevention of recurrent vasovagal syncope
90. Treatment of malignant neurocardiogenic syncope with dual chamber cardiac pacing and fluoxetine hydrochloride
91. Tilting towards a diagnosis in recurrent unexplained syncope
92. The North American vasovagal pacemaker study: A randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope
93. Cardiac pacing for prevention of vasovagal syncope
94. Oral fluid therapy: A promising treatment for vasodepressor syncope
95. Randomized double-blind, placebo-controlled trial of oral atenolol in patients with unexplained syncope and positive upright tilt table test results
96. The pressor actions of noradrenaline, angiotensin II, and saralasin in chronic autonomic failure treated with fludrocortisone
97. A randomized trial of sertraline versus atenolol and isopyramide in the treatment of neurogenic syncope
98. Randomized comparison of atenolol and fludrocortisone acetate in the treatment of pediatric neurally mediated syncope
99. The potential role of serotonin in the pathogenesis of neurocardiogenic syncope and related autonomic disturbances
100. Effects of paroxetine hydrochloride, a selective serotonin reuptake inhibitor, on refractory vasovagal syncope: A randomized, double-blind, placebo-controlled study
101. Midodrine: A review of its pharmacological properties and therapeutic use in orthostatic hypotension and secondary hypotensive disorders
102. Effects of alpha adrenoceptor agonists on cardiac output and blood pressure in spinally anesthetized ganglion blocked dogs
103. A comparison of postspace-flight orthostatic intolerance to vasovagal syncope and autonomic failure and the potential use of the alpha agonist midodrine for these conditions
104. Neurogenic orthostatic hypotension: A double-blind placebo-controlled study with midodrine
105. Outcome of biofeedback-assisted relaxation for neurocardiogenic syncope and headache: A clinical replication series
106. Changes in cerebral blood flow velocity associated with biofeedback-assisted relaxation treatment of migraine headaches are specific for the middle cerebral artery
107. Effect of biofeedback-assisted relaxation on migraine headache and changes in cerebral blood flow velocity in the middle cerebral artery
108. Characterization of subcutaneous microvascular blood flow during tilt table-induced neurally mediated syncope
109. Neurocardiogenic syncope: Response to hormonal therapy
110. Treatment of orthostatic hypotension with erythropoietin